This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Humanigen Past Earnings Performance

Past criteria checks 0/6

Humanigen's earnings have been declining at an average annual rate of -42.3%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 67.8% per year.

Key information

-42.3%

Earnings growth rate

-8.8%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate67.8%
Return on equityn/a
Net Margin-3,156.8%
Last Earnings Update31 Mar 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Humanigen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:0KB2 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 232-54150
31 Dec 223-71160
30 Sep 223-1091626
30 Jun 224-15219-97
31 Mar 224-19223-60
31 Dec 214-237230
30 Sep 213-235230
30 Jun 212-19925123
31 Mar 211-1531959
31 Dec 200-90160
30 Sep 200-59130
30 Jun 200-3161
31 Mar 200-1063
31 Dec 190-1063
30 Sep 190-1063
30 Jun 190-1073
31 Mar 190-972
31 Dec 180-1292
30 Sep 180-13103
30 Jun 180-18106
31 Mar 180-2299
31 Dec 170-22811
30 Sep 170-24713
30 Jun 170-21811
31 Mar 170-27911
31 Dec 160-27810
30 Sep 160-351111
30 Jun 160-371113
31 Mar 160-311112
31 Dec 150-351315
30 Sep 150-321019
30 Jun 150-331020
31 Mar 150-371124
31 Dec 140-381027
30 Sep 140-391019
30 Jun 140-421014
31 Mar 140-4498
31 Dec 130-4280
30 Sep 130-4380
30 Jun 130-4170
31 Mar 133-3160
31 Dec 126-2450

Quality Earnings: 0KB2 is currently unprofitable.

Growing Profit Margin: 0KB2 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0KB2 is unprofitable, and losses have increased over the past 5 years at a rate of 42.3% per year.

Accelerating Growth: Unable to compare 0KB2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0KB2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).


Return on Equity

High ROE: 0KB2's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies